Therefore, HER2-TTC possesses a dual mode of action through inhibiting both tumor growth and tumor-induced abnormal bone growth as demonstrated in the BT-474 breast cancer model mimicking the bone-metastatic disease. Here, ERBB2 is linked to breast carcinoma.